Grants Search Results

Rhabdomyosarcoma is an aggressive childhood cancer that often arises in muscle. Because of the poor survival, researchers are searching for genes underlying this cancer, with the hope of blocking them. A research scientist who studies how normal muscle forms found that a gene called MEST helps in defining muscle cell precursor identity. Dr. Linardic's lab had noticed that in rhabdomyosarcoma, MEST was highly expressed, suggesting that maybe MEST tricks cells into constantly growing. This project focuses on learning how MEST contributes to rhabdomyosarcoma, and how to block it.

By increasing physical activity, survivors may reduce their risk of obesity and chronic diseases, and improve their quality of life. Dr. Mendoza's research aims to examine the use of a wearable physical activity device, the Fitbit, paired with a Facebook group, to increase physical activity among teen childhood cancer survivors. This approach aims to harness new wearable technology and the widespread use of smart phones to use individual- and peer-influences to promote physical activity.

Childhood acute myeloid leukemia (AML) is the second most common leukemia in children, but causes the majority of leukemia related deaths. Current therapies do not adequately treat the disease and more than half of all children diagnosed with AML eventually relapse and die of their disease. Dr. Meshinchi recently performed a comprehensive genetic analysis of pediatric AML and identified mutations in CSF3R gene, the first pediatric-specific mutation in AML. This JJ's Angels St. Baldrick's Research Grant aims to study the function of this mutation to learn how it might be used as a therapeutic target.

This grant is named for the JJ's Angels Hero Fund created in memory of Julianna LaMonica to honor her joyful spirit and strength even in the midst of her battle with cancer. Her story continues to inspire so many to support the cause.

Based on progress to date, Dr. Moldovan was awarded new grants in 2018 and 2019 to fund additional years of this Scholar grant. Dr. Moldovan has identified a novel DNA damage repair mechanism that promotes the spread of leukemia cells. This research aims to investigate how leukemia cells fight DNA damage and potential therapies to target this mechanism.

Based on progress to date, Dr. Petrosiute was awarded new grants in 2018 and 2019 to fund additional years of this Scholar grant. Despite successes in treating children with certain types of cancers, outcome remains poor for children with advanced solid tumors, including brain tumors and sarcomas. Dr. Petrosiute has investigated a protein called Cdk5 in medulloblastoma, finding that tumors become vulnerable to immune cell killing when Cdk5 function is disrupted, and this disruption, which can be achieved by drugs currently being tested in Phase I clinical trials, was correlated with a diminished production of immune-protective molecule called PD-L1 on tumor cells. This research aims to identify the molecular mechanisms of Cdk5 in order to enhance immunotherapy treatments.

A portion of this grant was named for The Rebecca Allison Meyer Fund for Pediatric Cancer Research, a St. Baldrick's Hero Fund created to honor the memory of the joyful and spunky little girl who courageously battled brain cancer. Rebecca's legacy lives on in the funding of promising glioblastoma research.

Awarded at the Case Western Reserve University, and transferred to Vilnius University.

Survivors of pediatric brain tumors commonly struggle with progressive declines in attention and memory that emerge following neurosurgery, chemotherapy and radiation. Unfortunately, little is known about the neurobiological substrates of these cognitive dysfunctions. Dr. Posner's Grace for Good St. Baldrick's Supportive Care Grant aims to identify the specific changes in functional and structural brain connectivity that correlate with neurocognitive decline by collecting advanced magnetic resonance imaging (MRI) and neuropsychological test data on survivors. This data is being compared with healthy controls across three academic medical centers: Columbia University Medical Center, Children's Medical Center-Dallas and Seattle Children's Hospital.

This grant is named for the Grace for Good Fund created in honor of Grace Carey, a medulloblastoma survivor. It supports research of brain tumors and survivorship issues in the hopes of changing kids' lives for good.

Hepatoblastoma is the most common childhood liver cancer. Dr. Prochwnik is using models to investigate two mutant genes, SIRT3 and SIRT4, which normally work to balance metabolism and energy stores, that are commonly found in hepatoblastoma. This work aims to identify novel targets for cancer therapies in hepatoblastoma and other cancers.

Relapse continues to be the most common cause of failure after transplantation for childhood leukemia. Building upon studies completed in a previous funding period, the Pediatric Blood and Marrow Transplant Consortium will perform three trials over the next five years that will identify children with leukemia undergoing transplantation who are at especially high risk, and add a novel immunomodulatory or cellular therapeutic intervention to prevent relapse.

This grant is named for the Johnny Crisstopher Children's Charitable Foundation whose mission is to raise awareness of pediatric cancer and provide funds for research, treatment, and - ultimately - a cure. Famed illusionist Criss Angel founded the foundation in 2008 for charitable causes but it has now become his life's mission since his son, Johnny Crisstopher was diagnosed with leukemia in 2015 when he was 20 months old.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.